Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Crenolanib in D842V Mutated GIST
NCT02847429Phase 3Unknown
- Sponsor
- AROG Pharmaceuticals, Inc.
- Start
- Aug 2016
- Primary completion
- Aug 2021
- Modality
- Small Molecules
- Countries
- 7
01
Overview
A Phase 3 trial of crenolanib in gastrointestinal stromal tumor (GIST), sponsored by AROG Pharmaceuticals, Inc.. Status: unknown.
02
Drugs
crenolanib
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on NCT02847429.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02847429.